Combining the age-male-albumin-bilirubin-platelets score and shear wave elastography stratifies carcinogenic risk in hepatitis C patients after viral clearance

Table 2 Clinical parameters in the medium and high-risk group at follow-up 12 (n = 237)

	Non-carcinogenic group (n = 225)	Carcinogenic group (n = 12)	P value
Age (yr)	69.4 ± 9.1 (43-89)	71.8 ± 9.1 (51-84)	0.3371
Sex (male/female)	99/126	6/6	0.6835
ALT (IU/L)	17.3 ± 11.6 (4-123)	27.5 ± 21.5 (12-79)	0.0166
Total bilirubin (mg/dL)	1.23 ± 5.22 (0.11-7.90)	0.87 ± 0.29 (0.50-1.50)	0.9500
Alb (g/dL)	4.31± 0.35 (3.15-5.40)	4.31 ± 0.32 (3.67-4.69)	0.7828
WBC (104/mm3)	5.18 ± 1.61 (2.10-15.40)	5.00 ± 1.92 (1.90-8.40)	0.7036
Hb (g/dL)	13.7 ± 1.7 (9.8-19.1)	14.3 ± 1.0 (12.8-16.1)	0.2212
Plt (104/mm3)	18.6 ± 6.4 (2.9-38.6)	13.8 ± 6.7 (6.4-25.5)	0.0136
PT% (%)	94.8 ± 19.4 (29.4-156.4)	92.9 ± 19.1 (66.4-143.4)	0.4051
AFP (ng/mL)	4.2 ± 7.4 (0.6-100.5)	7.1 ± 5.7 (2.4-21.0)	0.0049
Vs (m/s)	1.45 ± 0.23 (0.95-2.14)	1.69 ± 0.24 (1.45-2.31)	0.0011
Fib-4 index	2.77 ± 2.00 (0.80-19.29)	4.33 ± 2.27 (1.44-7.98)	0.0049
Observation period (M)	33.8 ± 26.5 (6-83)	41.7 ± 21.7 (8-73)	0.1982

ALT: Alanine aminotransferase; WBC: White blood cell count; Plt: Platelet count; Alb: Serum albumin; PT%: Prothrombin time; AFP: Alpha-fetoprotein; Vs: Velocity of shear waves; Fib-4 index: Fibrosis-4 index.